Sanofi’s lunsekimig, a novel bispecific Nanobody® VHH, has shown promising results in recent Phase 2 clinical trials targeting chronic respiratory diseases. The AIRCULES phase 2b study demonstrated significant reductions in exacerbations and improvements in lung function for patients with moderate-to-severe asthma, while the DUET phase 2a study confirmed its efficacy in chronic rhinosinusitis with nasal polyps (CRSwNP) by achieving all primary and key secondary endpoints. Notably, lunsekimig effectively blocked both TSLP and IL-13, critical drivers of inflammation, indicating a dual-targeting mechanism that could transform respiratory disease management.

The significance of these findings lies in the substantial unmet need for effective treatments in asthma and CRSwNP, where over 50% of asthma patients remain poorly controlled despite existing therapies. The AIRCULES study reported a clinically meaningful improvement in pre-bronchodilator forced expiratory volume in one second (pre-BD FEV1), highlighting lunsekimig’s potential to enhance lung function and reduce healthcare utilization associated with exacerbations. In CRSwNP, improvements in nasal polyp scores and patient-reported symptoms further underscore the therapeutic promise of this dual-targeting approach.

A key implication of these studies is the potential shift in research paradigms toward combination therapies that target multiple inflammatory pathways simultaneously. As lunsekimig progresses into later-phase studies, including the ongoing AIRLYMPUS phase 2 and PERSEPHONE and THESEUS phase 3 studies, its development could streamline timelines for drug approval and reshape treatment strategies for chronic respiratory conditions, ultimately improving healthspan and quality of life for affected patients.

Source: globenewswire.com